These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19239365)

  • 21. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.
    Van Houtte M; Picchio G; Van Der Borght K; Pattery T; Lecocq P; Bacheler LT
    J Med Virol; 2009 Oct; 81(10):1702-9. PubMed ID: 19697398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
    Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
    Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
    Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
    J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy.
    Wittkop L; Commenges D; Pellegrin I; Breilh D; Neau D; Lacoste D; Pellegrin JL; Chêne G; Dabis F; Thiébaut R
    BMC Med Res Methodol; 2008 Oct; 8():68. PubMed ID: 18945369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Historical resistance profile helps to predict salvage failure.
    Zaccarelli M; Lorenzini P; Ceccherini-Silberstein F; Tozzi V; Forbici F; Gori C; Trotta MP; Boumis E; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2009; 14(2):285-91. PubMed ID: 19430103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
    Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy.
    Altmann A; Rosen-Zvi M; Prosperi M; Aharoni E; Neuvirth H; Schülter E; Büch J; Struck D; Peres Y; Incardona F; Sönnerborg A; Kaiser R; Zazzi M; Lengauer T
    PLoS One; 2008; 3(10):e3470. PubMed ID: 18941628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Within-host virus models with periodic antiviral therapy.
    De Leenheer P
    Bull Math Biol; 2009 Jan; 71(1):189-210. PubMed ID: 19083064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved therapy-success prediction with GSS estimated from clinical HIV-1 sequences.
    Pironti A; Pfeifer N; Kaiser R; Walter H; Lengauer T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19743. PubMed ID: 25397488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of Phenotypic Resistance Cutoffs From Routine Clinical Data.
    Pironti A; Walter H; Pfeifer N; Knops E; Lübke N; Büch J; Di Giambenedetto S; Kaiser R; Lengauer T;
    J Acquir Immune Defic Syndr; 2017 Apr; 74(5):e129-e137. PubMed ID: 27787339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological responses during a virologically failing antiretroviral regimen are associated with in vivo synonymous mutation rates of HIV type-1 env.
    Mens H; Jørgensen LB; Kronborg G; Schønning K; Benfield T
    Antivir Ther; 2009; 14(3):413-22. PubMed ID: 19474475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.
    Flandre P; Delaugerre C; Ghosn J; Chaix ML; Horban A; Girard PM; Gladysz A; Cohen-Codar I; Van PN; Taburet AM; Rouzioux C; Delfraissy JF;
    Antivir Ther; 2009; 14(1):93-7. PubMed ID: 19320241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ensemble Classifiers for Predicting HIV-1 Resistance from Three Rule-Based Genotypic Resistance Interpretation Systems.
    Raposo LM; Nobre FF
    J Med Syst; 2017 Aug; 41(10):155. PubMed ID: 28856560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead.
    Sosnik A; Chiappetta DA; Carcaboso AM
    J Control Release; 2009 Aug; 138(1):2-15. PubMed ID: 19445981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines.
    de Mendoza C; Anta L; García F; Pérez-Elías MJ; Gutiérrez F; Llibre JM; Menéndez-Arias L; Dalmau D; Soriano V
    AIDS Rev; 2009; 11(1):39-51. PubMed ID: 19290033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.